title: [Clinical evaluation of cefpodoxime proxetil in otorhinolaryngological infections].
abstract: In this study, we evaluated the clinical efficacy of cefpodoxime proxetil (CPDX-PR) in otorhinolaryngological infections. The subjects were 205 patients (85 men and 120 women) with various otorhinolaryngological infections, aged from 16 to 81 years (mean 49.2 years): 113 patients had acute infections, 25 patients had chronic infections and 67 patients had acute exacerbation of chronic infections. 1. Clinical evaluation The overall efficacy rate was 75.6%. When classified by disease, the efficacy rate was 84.9%, 60.0%, 65.6% in acute infections, chronic infections and acute exacerbation of chronic infections, respectively. 2. Bacteriological evaluation Frequencies of isolation of different organisms were studied: 49 strains of Staphylococcus aureus, 27 strains of Staphylococcus sp. and 15 strains of Streptococcus sp. were found in the decreasing order of frequencies. Antibacterial activities against S. aureus, Staphylococcus sp. and several other organisms were compared among CPDX-PR, ampicillin, cefaclor, cefteram and norfloxacin: CPDX-PR showed the highest activity. 3. Side effect Mild urticaria was observed in only 1 patient. Abnormal laboratory test results were mild elevation of GOT and GPT in 3 of 43 patients. Based on the above results, we consider that CPDX-PR is useful for treatment of otorhinolaryngological infections.
authors.affiliation: Department of Otolaryngology, Tottori University, Faculty of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Takeuchi
authors.forename: H
authors.initials: H
authors.lastname: Ikoma
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Nakajima
authors.forename: Y
authors.initials: Y
authors.lastname: Kouzaki
authors.forename: Y
authors.initials: Y
authors.lastname: Ishizu
authors.forename: H
authors.initials: H
authors.lastname: Makino
authors.forename: S
authors.initials: S
authors.lastname: Sugihara
authors.forename: S
authors.initials: S
authors.lastname: Ootawara
authors.forename: K
authors.initials: K
authors.lastname: Asagi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy* / Q000382:microbiology; D011355:Prodrugs / Q000494:pharmacology / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D000097627:Cefpodoxime Proxetil
chemical_list: D015296:Ceftizoxime; D011355:Prodrugs; D000097627:Cefpodoxime Proxetil